Abstract:

Objective To evaluate the clinical efficacy of Rebamipide in the treatment of nonsteroidal anti-inflammatory drugs (NSAIDs)-associated intestinal disease. Methods PubMed, MedLine, Embase, The Cochrane Library, China Biomedical Literature Database (CBM), CNKI and Wanfang Data were searched for randomized controlled trials(RCTs)in the treatment of NSAIDs-associated bowel diseases. Set a time limit for each database to be built until January 2021. According to the evaluation criteria recommended by the Cochrane system evaluation guide manual, the quality of the included study was evaluated, and Review Manager 5.3 software was used for Meta analysis after entering the main outcome indicators of the literatures. Results Finally, eligible 6 RCTs were included, with a total of 255 subjects; 3 articles mainly observed the number of cases of intestinal injury after treatment with Rebamipide, and all of them could extract effective data; the effective data could be extracted from 4 articles focused the number of intestinal mucosal erosion after treatment, 3 articles observed the number of intestinal mucosal ulcers after treatment with extracted effective data. The results of Meta analysis showed that the number of intestinal injuries (OR=0.34, 95%CI: 0.15-0.75, P<0.05), intestinal mucosal erosion(MD=-4.71, 95%CI:-6.40 to -3.02, P<0.05) and intestinal mucosal ulcers (MD =-0.45, 95% CI: -0.89 to -0.01, P<0.05) decreased significantly in the Rebamipide group as compared to the routine regimen group. Conclusion Rebamipide has advantages in the prevention and treatment of NSAIDs-associated intestinal disease and can reduce intestinal injury in patients who take NSAIDs drugs for a long time.

Key words: NSAIDS-related intestinal disease, Rebamipide, efficacy, Meta-analysis